Innate immunity

FCRL6 distinguishes mature cytotoxic lymphocytes and is upregulated in patients with B-cell chronic lymphocytic leukemia

  1. Daniel M. Schreeder1,
  2. Jicun Pan2,3,
  3. Fu Jun Li2,3,
  4. Eric Vivier4,5,6,7,
  5. Randall S. Davis1,2,3,8,*

Article first published online: 7 NOV 2008

DOI: 10.1002/eji.200838516

Issue

European Journal of Immunology

European Journal of Immunology

Volume 38, Issue 11, pages 3159–3166, November 2008

Additional Information

How to Cite

Schreeder, D. M., Pan, J., Li, F. J., Vivier, E. and Davis, R. S. (2008), FCRL6 distinguishes mature cytotoxic lymphocytes and is upregulated in patients with B-cell chronic lymphocytic leukemia. Eur. J. Immunol., 38: 3159–3166. doi: 10.1002/eji.200838516

Author Information

  1. 1

    Department of Microbiology, University of Alabama at Birmingham, Birmingham, AL, USA

  2. 2

    Division of Hematology/Oncology, University of Alabama at Birmingham, Birmingham, AL, USA

  3. 3

    Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA

  4. 4

    Centre d'Immunologie de Marseille-Luminy, Université de la Méditerranée, Campus de Luminy, Marseille, France

  5. 5

    INSERM, U631, Campus de Luminy, Marseille, France

  6. 6

    CNRS, UMR6102, Campus de Luminy, Marseille, France

  7. 7

    Hôpital de la Conception, Assistance Publique – Hôpitaux de Marseille, Marseille, France

  8. 8

    Department of Biochemistry and Molecular Genetics, University of Alabama at Birmingham, Birmingham, AL, USA

*University of Alabama at Birmingham, 1825 University Blvd SHEL 412, Birmingham, AL 35294-2182, USA Fax: +1205-934-1875

Publication History

  1. Issue published online: 7 NOV 2008
  2. Article first published online: 7 NOV 2008
  3. Manuscript Accepted: 21 AUG 2008
  4. Manuscript Revised: 14 AUG 2008
  5. Manuscript Received: 16 MAY 2008

Funded by

  • National Institutes of Health. Grant Number: AI55638
  • Dana Foundation Program in Human Immunology
  • V Foundation for Cancer Research
  • Howard Hughes Medical Institute Medical Research Training Fellow
  • Dana Foundation Program in Human Immunology Trainee
  • National Institutes of Health training. Grant Number: AI007051
  • UAB Medical Scientist Training Program

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article with Supporting Information (HTML) Get PDF (242K)

Keywords:

  • Chronic lymphocytic leukemia;
  • Fc receptor-like;
  • Human cytotoxic T cells;
  • Human NK cells

Abstract

Fc receptor-like 6 (FCRL6), the most recently characterized member of the FCRL family, is a cell surface glycoprotein with tyrosine-based regulatory potential. An extensive survey of human hematopoietic tissues disclosed that FCRL6 expression by NK- and T-cell subpopulations increases as a function of differentiation and is remarkably restricted to mature lymphocytes with cytotoxic capability. In particular, FCRL6 distinguishes perforin-expressing CD56dim NK cells, Vδ1+ and Vδ2+ γδ T cells, effector and effector memory CD8+ T cells, and rare cytotoxic CD4+ T cells in adult tissues. Analysis of this receptor in B-cell chronic lymphocytic leukemia (CLL) was also performed. FCRL6 was found to mark significantly expanded populations of cytotoxic CD8+ T, CD4+ T, and NK cells in patients with CLL. Despite sequence homology with the known Fc receptors for IgG and IgE, FCRL6 did not bind Ig. Although FCRL6 can be tyrosine-phosphorylated, its antibody-mediated ligation was unable to influence cellular activation. Collectively, these results demonstrate that FCRL6 is a distinct indicator of cytotoxic effector lymphocytes that is upregulated in diseases characterized by chronic immune stimulation.

View Full Article with Supporting Information (HTML) Get PDF (242K)